The estimated Net Worth of Jeff L Vacirca is at least $418 Tisíc dollars as of 11 June 2024. Jeffrey Vacirca owns over 10,000 units of Spectrum Pharmaceuticals stock worth over $155,694 and over the last 7 years he sold SPPI stock worth over $0. In addition, he makes $262,115 as Independent Director at Spectrum Pharmaceuticals.
Sign up
Jeffrey Vacirca SPPI stock SEC Form 4 insiders trading
Jeffrey has made over 5 trades of the Spectrum Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of SPPI stock worth $11,100 on 11 June 2024.
The largest trade he's ever made was buying 50,000 units of Spectrum Pharmaceuticals stock on 30 November 2022 worth over $22,500. On average, Jeffrey trades about 2,973 units every 85 days since 2017. As of 11 June 2024 he still owns at least 151,159 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Jeffrey Vacirca stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Vacirca biography
Dr. Jeffrey L. Vacirca M.D. serves as Independent Director of the Company. Since 2008, Dr. Vacirca has served as Chief Executive Officer, Managing Partner and Director of Clinical Research at New York Cancer and Blood Specialists, a cancer care center specializing in hematology/oncology and medical oncology. Since 2011, he has served as President and Co-Founder of National Translational Research Group, a group focusing on non-clinical research, and since 2012 has served as a Medical Director and Strategic Advisor for the International Oncology Network specialty group at Amerisource Bergen, a pharmaceutical products company. Since 2018, he has served as the Medical Director of the Oncology Network Development at Mount Sinai Health Network and as an associate clinical professor at Icahn School of Medicine at Mount Sinai, New York.
What is the salary of Jeffrey Vacirca?
As the Independent Director of Spectrum Pharmaceuticals, the total compensation of Jeffrey Vacirca at Spectrum Pharmaceuticals is $262,115. There are 11 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.
How old is Jeffrey Vacirca?
Jeffrey Vacirca is 51, he's been the Independent Director of Spectrum Pharmaceuticals since 2018. There are 10 older and 4 younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.
What's Jeffrey Vacirca's mailing address?
Jeff's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.
Insiders trading at Spectrum Pharmaceuticals
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen a Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
What does Spectrum Pharmaceuticals do?
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
What does Spectrum Pharmaceuticals's logo look like?
Complete history of Jeffrey Vacirca stock trades at Spectrum Pharmaceuticals, Odonate Therapeutics Inc a Assertio
Spectrum Pharmaceuticals executives and stock owners
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Joseph Turgeon,
President, Chief Executive Officer, Director -
Thomas Riga,
Chief Operating Officer, Chief Commercial Officer, Executive Vice President -
Kurt Gustafson,
Chief Financial Officer, Executive Vice President -
Keith McGahan,
Senior Vice President, Chief Legal Officer, Corporate Secretary -
Francois Lebel,
Executive Vice President, Chief Medical Officer -
Thomas J. Riga,
Pres, CEO & Director -
Kurt A. Gustafson,
Exec. VP & CFO -
Dr. Francois J. Lebel FRCPC, M.D.,
Exec. VP & Chief Medical Officer -
Keith M. McGahan J.D., L.L.M.,
Exec. VP, Chief Legal Officer & Corp. Sec. -
William Ashton,
Independent Chairman of the Board -
Bernice Welles,
Independent Director -
Jeffrey Vacirca,
Independent Director -
Dolatrai Vyas,
Independent Director -
Elizabeth Czerepak,
Independent Director -
Seth Fischer,
Independent Director -
Lyndah Dreiling,
Senior Vice President, Clinical Development -
Dr. Lyndah K. Dreiling M.B.A., M.D.,
Sr. VP of Clinical Devel. -
Lisa A. Croissant,
VP of Sales -
Alberto Dejesus,
VP of Marketing -
Bimal R. Shah,
VP of Corp. & Bus. Devel. -
Anthony E Iii Maida,
Director -
Raymond W Cohen,
Director -
Stuart Mitchell Krassner,
Director -
Gilles Gagnon,
Director -
Luigi Md Lenaz,
President, Oncology Division -
Juhyun Lim,
Director -
Jeff L Vacirca,
Director -
Ann C Phd Kessler,
Director -
Armin M Kessler,
Director -
Lee F Md Ph D Allen,
Chief Medical Officer -
Joseph Kenneth Keller,
EVP & Chief Operating Officer -
Carol Phd Ocleireacain,
Director -
Paul H Phd Silverman,
Director -
Shyam K Kumaria,
Vice President Finance -
Mark J Glasky,
Director -
Krishan K Arora,
Director -
Eric L Phd Nelson,
Director -
John L Mcmanus,
VP,Finance, Strategic Planning -
Rajesh C Md Shrotriya,
Ch, Pres. and Chief Exec. Off. -
Julius A Vida,
Director -
Dilip J Md Phd Mehta,
Director -
Richard Fulmer,
Director -
James Shields,
Chief Commercial Officer -
Brett L Scott,
Acting Chief Financial Officer -
Anton Gueth,
Director -
Mitchell P. Cybulski,
Director -
George F Tidmarsh,
CSO AND HEAD OF R&D OPERATIONS -
Nora Brennan,
See Remarks